VERAXA Biotech AG (NASDAQ: VRXA) provided a corporate and pipeline update on Wednesday, detailing progress during the first half of 2026. The company emphasized continued advancement of its proprietary BiTAC(R) platform and growing interest from potential pharmaceutical partners.
The pipeline now includes four BiTAC-based T-cell engager programs targeting solid tumors, two bispecific antibody-drug conjugate (ADC) programs, and two non-BiTAC assets available for partnering. VERAXA plans to prioritize investment in its BiTAC portfolio while seeking to monetize selected non-BiTAC programs to finance future development, with the goal of advancing lead BiTAC-TCE candidate VXA-102 to IND/CTA readiness by early 2028.
Company executives cited strong industry interest in T-cell engager and ADC technologies, noting that recent partnering discussions at the BIO International Convention and other scientific meetings reinforced confidence in the company's differentiated BiTAC platform and its potential to secure strategic collaborations. VERAXA said it continues to refine both its pipeline and partnering strategy as it advances its next generation of cancer therapies.
According to the press release, the company's BiTAC platform is designed to overcome limitations of conventional T-cell engagers, potentially offering improved efficacy and safety. The platform is built on scientific breakthroughs from the European Molecular Biology Laboratory (EMBL). The full press release is available at https://ibn.fm/xTF5q.
VERAXA's strategy reflects a broader trend in biotech where companies leverage platform technologies to attract partnerships and funding. The focus on solid tumors addresses a significant unmet medical need, as many existing T-cell engagers are approved only for hematological malignancies. The company's ability to advance VXA-102 to regulatory filing readiness by early 2028 will be a key milestone.
For more information on VERAXA Biotech, visit the company's newsroom at http://ibn.fm/VRXA.
